Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.

Women Remain Most at Risk of Brain Vein Clots After J&J Vaccine

MedPage Today reported:

Incidence of cerebral venous sinus thrombosis (CVST) remained a rare occurrence after the Johnson & Johnson COVID-19 adenovirus vector vaccine began being administered, researchers said.

Those at highest risk of CVST after receiving the Johnson & Johnson product in early 2021 were women ages 30 to 39 (26.52 per 100,000 person-years) and women ages 40 to 49 (29.48 per 100,000 person-years) — with women in general having a 5.1-fold higher risk after vaccination than they did before the COVID pandemic (13.01 vs 2.53 per 100,000 person-years, P<0.001).

CDC Panel Unanimously Recommends Pfizer COVID Vaccine for Kids Ages 5 to 11 in Critical Step Toward Clearance

CNBC reported:

A key Centers for Disease Control and Prevention advisory committee on Tuesday voted to recommend doses of Pfizer’s and BioNTech’s COVID-19 vaccine for children ages 5 to 11, one of the last steps before pediatricians can begin administering shots to as many as 28 million eligible kids in the U.S.

CDC Director Dr. Rochelle Walensky will now consider whether to accept the recommendation by the agency’s Advisory Committee on Immunization Practices. If she signs off, which is expected as early as late Tuesday, vaccinations for young kids could begin immediately.

White House Says 15 Million COVID Shots Will Roll Out to Children by Next Week

Reuters reported:

The United States is rolling out Pfizer/BioNTech COVID-19 vaccines for children aged 5 to 11 this week, but most of the 15 million shots being shipped initially are unlikely to be available before next week, the White House said on Monday.

Millions of doses specifically formulated for children of that age group will start arriving at distribution centers over the next few days, White House coronavirus response coordinator Jeff Zients said, and the federal government has purchased enough supply for all eligible 28 million children.

COVID: Medical Experts Step up After Dismissing Menstrual Changes

ALJAZEERA reported:

Thousands of women have reported temporary changes to their regular menstrual patterns, including delays, heavier vaginal bleeding or more physical pain. Irregularities have been reported with all vaccines and in various countries.

Following a chorus of calls, efforts are now underway to investigate potential links. Those reviewing the issue include the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), after it received reports by more than 30,000 women and two US-based medical researchers who have collected more than 140,000 reports so far.

Immunity From Both Vaccines, COVID Infection Last at Least Six Months: CDC

The Hill reported:

Immunity from COVID-19 lasts at least six months when one takes a vaccine or gets infected by the disease, according to a science brief released by the Centers for Disease Control and Prevention (CDC).

The brief looks at peer-reviewed and preprint data, as well as data that is unpublished by the CDC, to compare infection-induced immunity to vaccine-induced immunity.

The agency said that available evidence shows that those who are fully vaccinated and those who have previously had COVID-19 each have “a low risk of subsequent infection for at least six months.”

Elevated Risk of Clots in J&J Vaccine Recipients, Says Mayo Clinic Study

The Washington Times reported:

Recipients of the Johnson & Johnson COVID-19 vaccine were more likely to experience a rare blood clotting issue than persons in the general population before the pandemic, according to a study published Monday by JAMA Internal Medicine.

Mayo Clinic researchers gathered data on rates of the clotting disorder in Olmsted County, Minnesota, from 2001 to 2015 and compared it to rates of the issue among the population that received the one-shot J&J vaccine.

It found persons in the latter group were 3.5 more likely to develop cerebral venous sinus thrombosis (CVST) than the pre-pandemic group, after adjusting for factors such as sex and age to make a direct comparison.

Mild COVID Not Linked to Long-Term Cardiac Damage — Prospective Study Shows No Evidence of Myocarditis

MedPage Today reported:

Compared with seronegative healthcare workers, those who had generally mild SARS-CoV-2 had no differences in cardiac structure, function, MRI markers of myocarditis, or cardiac injury biomarkers 6 months later, James Moon, MD, of St. Bartholomew’s Hospital in London, and colleagues reported in JACC: Cardiovascular Imaging.

“Thus, screening in asymptomatic patients following nonhospitalized COVID-19 is currently not indicated,” the group concluded, pointing to it as yet more evidence counteracting an early but alarming finding that 78% of COVID survivors had lingering myocardial inflammation and other cardiac MRI abnormalities.

Monoclonal Antibody Cocktail Effectively Neutralizes Delta Variant: Study

The Times of India reported:

In the first study to test the effectiveness of monoclonal antibody (mAb) cocktail against the dreaded Delta variant, Hyderabad-based AIG Hospitals along with the Asian Healthcare Foundation, CCMB Hyderabad and Institute of Life Sciences, has found that the therapy is able to neutralize the Delta variant and reduces severe disease and death in infected high-risk individuals by 100%.

Elaborating on the findings of the study, AIG Hospitals chairman Dr D Nageshwar Reddy said that 75% of the patients that received the mAb therapy became RT-PCR negative by Day 7 and 78% of patients got relieved of their clinical symptoms like fever, cough by the 7th day.

Also, none of the participants developed severe disease or died, there was no increase in inflammatory markers, which causes severe disease, in these patients and on follow-up none of the patients reported any post-Covid syndrome, Dr Reddy said.